{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:17:20Z","timestamp":1783484240087,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"DOI":"10.7759\/cureus.112239","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:12:46Z","timestamp":1783483966000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Jenika","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00638","article-title":"Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology","volume":"10","author":"Gevaert AB","year":"2019","unstructured":"Gevaert AB, Boen JR, Segers VF, Van Craenenbroeck EM. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol. 2019, 10:638. 10.3389\/fphys.2019.00638","journal-title":"Front Physiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart\u00a0failure\u00a0with reduced versus preserved\u00a0ejection fraction","volume":"64","author":"Mentz RJ","year":"2014","unstructured":"Mentz RJ, Kelly JP, von Lueder TG, et al.. Noncardiac comorbidities in heart\u00a0failure\u00a0with reduced versus preserved\u00a0ejection fraction. J Am Coll Cardiol. 2014, 64:2281-93. 10.1016\/j.jacc.2014.08.036","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah KS","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, et al.. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017, 70:2476-86. 10.1016\/j.jacc.2017.08.074","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","volume":"31","author":"Waqas SA","year":"2025","unstructured":"Waqas SA, Sohail MU, Saad M, et al.. Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2025, 31:1076-80. 10.1016\/j.cardfail.2025.01.022","journal-title":"J Card Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-as01","article-title":"Standards of medical care in diabetes-2022 abridged for primary care providers","volume":"40","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2022 abridged for primary care providers. Clin Diabetes. 2022, 40:10-38. 10.2337\/cd22-as01","journal-title":"Clin Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.12.006","article-title":"Effect of glucagon-like peptide-1 receptor agonists on prognosis of heart failure and cardiac function: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Huixing L","year":"2023","unstructured":"Huixing L, Di F, Daoquan P. Effect of glucagon-like peptide-1 receptor agonists on prognosis of heart failure and cardiac function: a systematic review and meta-analysis of randomized controlled trials. Clin Ther. 2023, 45:17-30. 10.1016\/j.clinthera.2022.12.006","journal-title":"Clin Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biom15091342","article-title":"Role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with chronic heart failure","volume":"15","author":"Llongueras-Esp\u00ed P","year":"2025","unstructured":"Llongueras-Esp\u00ed P, Garc\u00eda-Romero E, Com\u00edn-Colet J, Gonz\u00e1lez-Costello J. Role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with chronic heart failure. Biomolecules. 2025, 15:1342. 10.3390\/biom15091342","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile MR","year":"2025","unstructured":"Zile MR, Borlaug BA, Kramer CM, et al.. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation. 2025, 151:656-68. 10.1161\/CIRCULATIONAHA.124.072679","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley RE","year":"2024","unstructured":"Pratley RE, Tuttle KR, Rossing P, et al.. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol. 2024, 84:1615-28. 10.1016\/j.jacc.2024.08.004","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","unstructured":"ATS statement. guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166:111-7. 10.1164\/ajrccm.166.1.at1102","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman M","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al.. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011, 20:1727-36. 10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.08.046","article-title":"Patient Global Impression of Severity scale in chronic cough: validation and formulation of symptom severity categories","volume":"11","author":"Rhatigan K","year":"2023","unstructured":"Rhatigan K, Hirons B, Kesavan H, et al.. Patient Global Impression of Severity scale in chronic cough: validation and formulation of symptom severity categories. J Allergy Clin Immunol Pract. 2023, 11:3706-12.e1. 10.1016\/j.jaip.2023.08.046","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.07.017","article-title":"New York Heart Association functional class predicts exercise parameters in the current era","volume":"158","author":"Russell SD","year":"2009","unstructured":"Russell SD, Saval MA, Robbins JL, et al.. New York Heart Association functional class predicts exercise parameters in the current era. Am Heart J. 2009, 158:S24-30. 10.1016\/j.ahj.2009.07.017","journal-title":"Am Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101602","article-title":"The safety and efficacy of GLP-1 receptor agonists in heart failure patients: a systematic review and meta-analysis","volume":"48","author":"Merza N","year":"2023","unstructured":"Merza N, Akram M, Mengal A, et al.. The safety and efficacy of GLP-1 receptor agonists in heart failure patients: a systematic review and meta-analysis. Curr Probl Cardiol. 2023, 48:101602. 10.1016\/j.cpcardiol.2023.101602","journal-title":"Curr Probl Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000915","article-title":"Efficacy of semaglutide and other GLP-1 agonists in patients with heart failure with preserved ejection fraction and obesity: a systemic review and meta-analysis","author":"Beshr MS","year":"2025","unstructured":"Beshr MS, Shembesh RH, Kara AO, Salama AH, Arhaym E, Abuajamieh M, Elhadi M. Efficacy of semaglutide and other GLP-1 agonists in patients with heart failure with preserved ejection fraction and obesity: a systemic review and meta-analysis. Cardiol Rev. 2025, 10.1097\/CRD.0000000000000915","journal-title":"Cardiol Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70234","article-title":"GLP-1 and dual GLP-1\/GIP receptor agonists in heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","volume":"48","author":"Ahmed M","year":"2025","unstructured":"Ahmed M, Burhan M, Shafiq A, et al.. GLP-1 and dual GLP-1\/GIP receptor agonists in heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis. Clin Cardiol. 2025, 48:e70234. 10.1002\/clc.70234","journal-title":"Clin Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/511375-glucagon-like-peptide-1-glp-1-based-therapies-and-heart-failure-outcomes-a-scoping-review-of-contemporary-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:12:48Z","timestamp":1783483968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/511375-glucagon-like-peptide-1-glp-1-based-therapies-and-heart-failure-outcomes-a-scoping-review-of-contemporary-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.112239","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}